BioPharm International Editors

Articles

FDA Recommends Inclusion of Omicron BA.4/5 Component for COVID-19 Vaccine Booster Doses

Following the recommendation of an independent vaccine panel, FDA is advising vaccine manufacturers to include an Omicron BA.4 and BA.5 component to their booster doses.

Getinge Launches New DPTE-EXO with Sleeveless DPTE-BetaBag for Aseptic Transfer

Getinge’s new DPTE-EXO with Sleeveless DPTE-BetaBag is an alpha port with an external opening and an integrated funnel for automated aseptic transfer.

Ipsen Expands Oncology Portfolio with $247 Million Epizyme Acquisition

Ipsen will acquire Epizyme, who recently had their lead medicine Tazverik (tazemetostat) approved by FDA for treatment of relapsed or refractory follicular lymphoma.

Inceptor Bio Collaborates with University of Minnesota to Develop Cell Therapy Platform

Inceptor Bio and the University of Minnesota aim to build a novel iPSC platform to accelerate cell therapy drug development.

MilliporeSigma to Supply Lotte Biologics with Biologics Manufacturing Capabilities in US

MilliporeSigma and Lotte Group will collaborate on facility design and workforce training for a new biologics business unit in the US.

Avantor Partners with GeminiBio on Custom Hydrated Solutions and Cell Culture Media

Under the collaboration, Avantor and GeminiBio will offer custom cGMP solutions to enhance process efficiency and accelerate speed-to-market of novel emerging therapy modalities.

Cosentyx Receives Expanded Approvals in EU for Use in Childhood Arthritic Conditions

The European Commission has approved Cosentyx for the treatment of various childhood arthritic conditions.

Xenpozyme Approved by EC for the Treatment of ASMD

The European Commission has approved Xenpozyme as the first treatment for ASMD.

FDA Releases Action Plan for Rare Neurodegenerative Diseases

The action plan will span over five years and will fulfill a requirement of the Accelerating Access to Critical Therapies for ALS Act.

MilliporeSigma Intensifies Upstream Processing with New BioContinuum Seed Train Platform Offering

MilliporeSigma’s new BioContinuum Seed Train Platform offering enables a fully closed bioprocessing environment for both fed-batch and perfusion N-production.